Note ONTY/Merck would not be the only one jumping on the Mucin bandwagon, there is also Transgene/Novartis.
Back when I was following ONTY more closely I looked at Transgene's TG4010 muc1 vaccine as a comparator. It's different from Stimuvax in that it's a littler longer than a 5 repeat sequence of the core muc1 peptide in a poxvirus delivery vehicle. Redplate posted once that it was to get around the basic muc1 patents that ONTY licensed. Transgene ran a ph II combo trial in stage III/IV NSCLC with similar OS result in terms of ITT missed, but a sub-group was found that was lo and behold stat sig. I haven't followed it since but Transgene was looking to move to ph III.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.